What the FDA labels say about taking them together
Everolimus and palbociclib
Palbociclib's FDA label of July 2, 2026 names everolimus in its drug interactions section; the everolimus labels PlainMeds reads (2) do not name palbociclib. The palbociclib label: “The dose of the sensitive CYP3A substrate with a narrow therapeutic index may need to be reduced, as IBRANCE may increase its exposure.”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the everolimus label say about palbociclib?
Everolimus's label (effective June 1, 2026) and its 1 other brand-application label do not name palbociclib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the palbociclib label say about everolimus?
Palbociclib label, drug interactionsThe dose of the sensitive CYP3A substrate with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) may need to be reduced, as IBRANCE may increase its exposure [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Palbociclib | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | Breast cancer |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | n/a |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once